Eli Lilly's 22.75 Billion Trading Volume Ranks 19th Amidst Cancer Research and Liver Disease Acquisitions

On March 25, 2025, Eli Lilly and Company (LLY) saw a trading volume of 22.75 billion, ranking 19th in the day's stock market activity. The stock price decreased by 1.45%.

Eli Lilly and Company is set to present preclinical data on agents targeting SMARCA2 and multiple KRAS mutations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will focus on the potential of these agents in cancer treatment, which could significantly impact the company's stock performance.

In addition to the AACR presentations, Eli Lilly has also announced the acquisition of all commercial and intellectual property rights to Organovo's FXR program. This acquisition includes the lead asset FXR314, which will be developed worldwide by Eli Lilly. The deal is expected to enhance Eli Lilly's portfolio in the field of liver diseases, potentially driving future growth and investor interest.